Singapore markets closed

ORIC Pharmaceuticals, Inc. (ORIC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.16+0.14 (+1.55%)
At close: 04:00PM EDT
9.65 +0.49 (+5.35%)
After hours: 05:37PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.02
Open8.99
Bid9.11 x 400
Ask9.21 x 100
Day's range8.69 - 9.30
52-week range4.91 - 16.65
Volume368,159
Avg. volume568,529
Market cap617.588M
Beta (5Y monthly)1.18
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

    Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025 Presented initial ORIC-944 Phase 1b monotherapy data demonstrating potential best-in-class profile with strong pharmacokinetic, pharmacodynamic, and safety results in patients with prostate cancer; proceeding into combination with AR inhibitor(s) in metastatic prostate cancer Presented updat

  • GlobeNewswire

    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO and SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2024 (the “Grant Date”), ORIC granted a total of 14,500 non-qualified stock options and 2,300 restricted stock units to two new non-executive employees who began their employment with ORIC in April 2024. These inducement grants were granted

  • GlobeNewswire

    ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

    Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to evaluate ORIC-114 for the treatment of patients with first-line, treatment-naïve EGFR exon 20 NSCLC Expect to report updated Phase 1b data in the first half of 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC